Latanoprost Sandoz

Latanoprost, the active ingredient in Latanoprost Sandoz, is a Prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to prevent optic nerve damage and preserve visual function through increased uveoscleral outflow of aqueous humor.

GNH USA supplies Latanoprost Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Latanoprost belongs to the prostaglandin analog class and is used to manage ocular conditions characterized by elevated intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces intra‑ocular pressure to prevent development of glaucoma. Secondary open‑angle glaucoma: decreases intra‑ocular pressure when other causes are present.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness or hyperemia. - Itching or mild irritation of the eye. - Blurred vision shortly after instillation. - Increased brown pigmentation of the iris. - Lengthening and darkening of eyelashes. - Periocular skin darkening.

Serious or Rare Side Effects: - Severe eye pain or acute inflammation. - Sudden loss of vision. - Allergic reactions such as swelling of the eyelids or conjunctiva. - Uveitis or iritis. - Corneal edema or endothelial damage. - Persistent ocular infection.

Before initiating therapy, clinicians should evaluate patient suitability and monitor ocular health. - Assess baseline intra‑ocular pressure: ensure accurate measurement prior to treatment. - Monitor iris color changes: inform patients that pigmentation may be permanent. - Avoid use in active ocular inflammation: may exacerbate condition. - Counsel on eyelash growth: advise patients of possible cosmetic changes. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may increase ocular irritation. - Combination with ocular cycloplegics: may reduce IOP‑lowering effect. - Use with systemic carbonic anhydrase inhibitors: additive IOP reduction, monitor closely.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may heighten ocular irritation. - Topical corticosteroids: may diminish IOP‑lowering efficacy. - Beta‑blocker eye drops: additive IOP reduction, require monitoring.